Literature DB >> 3169619

Prognostic significance of endometrial extension in carcinoma of the cervix.

L Grimard1, P Genest, A Girard, L Gerig, M Prefontaine, P Drouin, R C Nair, M Stats.   

Abstract

A retrospective analysis of 343 consecutive patients with histologically proven carcinoma of the cervix, treated at the Ottawa General Hospital, was undertaken to evaluate the prognostic significance of endometrial extension. All these patient had a D + C as part of their work-up. Sixty-seven patients had a (+) D + C: 34/150 (23%) in Stage IB, 21/106 (20%) in Stage II, and 12/87 (14%) in Stage III. Survival was closely related to the D + C findings in early stages. In Stage IB, the 5-year survival of D + C (-) patients was 90% vs 50% in D + C (+) patients (P less than 0.003) and in Stage II, the 5-year survival was 77% and 55%, respectively (P = 0.089). There was, however, no difference in survival in Stage III patients (35% vs 29%). Pelvic failures were similar in both groups, stage for stage, but those with a (+) D + C had a higher incidence of distant metastasis. In Stage IB, distant metastases were found in 8.5% (10/116) of D + C (-) patients compared to 38% (13/34) in D + C (+) patients (P less than 0.001) and in Stage II, in 18.5% (16/85 and 33% (7/21) of the patients (P = 0.126), respectively. There was no difference in Stage III patients (28% vs 25%). This study suggests that endometrial extension is a significant prognostic factor in early stages and is associated with a higher risk of distant metastases. Management of these high risk patients is discussed.

Entities:  

Mesh:

Year:  1988        PMID: 3169619     DOI: 10.1016/s0090-8258(88)80008-8

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  1 in total

1.  Uterine corpus invasion in cervical cancer: a multicenter retrospective case-control study.

Authors:  Weili Li; Fangjie He; Ping Liu; Hui Duan; Yan Ni; Shaoguang Wang; Lihong Lin; Zhaohong Yin; Xiaolin Chen; Lu Yin; Lixia Wang; Yueping Liu; Zhonghua Luan; Chunlin Chen
Journal:  Arch Gynecol Obstet       Date:  2021-02-05       Impact factor: 2.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.